State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, China.
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Rd, Shanghai 201203, China.
Biomater Sci. 2022 Dec 20;11(1):62-75. doi: 10.1039/d2bm01252a.
Liposomal technology has been widely used in the pharmaceutical field for the preparation of nano-sized drug delivery systems based on natural or synthetic lipids. Liposomes possess many attractive properties, such as easy processing, high biocompatibility, adaptable drug loading, and improved PK profiles. In recent decades, great efforts have been made in this field, and dozens of liposomal medicines have been marketed worldwide and many more are under preclinical or clinical investigations. Liposomes can enhance the aqueous dissolution and stability of the encapsulated drugs and modulate the fate of the drugs (, prolonged half-life and increased drug accumulation in the pathological sites). Therefore, liposomal technology can improve the druggability of the candidates, enhance treatment efficacy and reduce side effects. This review discusses the prospects of liposomal delivery, including the specific considerations of innovation and challenges.
脂质体技术已广泛应用于制药领域，用于制备基于天然或合成脂质的纳米级药物传递系统。脂质体具有许多吸引人的特性，如易于加工、高生物相容性、可适应的药物负载以及改善的 PK 曲线。在过去的几十年中，该领域已经做出了巨大的努力，数十种脂质体药物已在全球上市，还有更多的药物正在进行临床前或临床研究。脂质体可以提高包封药物的水溶解度和稳定性，并调节药物的命运（，延长半衰期并增加药物在病变部位的积累）。因此，脂质体技术可以提高候选药物的成药性，增强治疗效果并降低副作用。本文讨论了脂质体递药的前景，包括创新和挑战的具体考虑。
